OMERS ADMINISTRATION Corp Sells 4,400 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

OMERS ADMINISTRATION Corp trimmed its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 21.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 15,700 shares of the medical equipment provider's stock after selling 4,400 shares during the period. OMERS ADMINISTRATION Corp's holdings in Lantheus were worth $1,405,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of LNTH. State of New Jersey Common Pension Fund D boosted its holdings in shares of Lantheus by 0.4% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 26,428 shares of the medical equipment provider's stock worth $2,364,000 after acquiring an additional 115 shares during the period. Bleakley Financial Group LLC boosted its holdings in shares of Lantheus by 6.1% in the fourth quarter. Bleakley Financial Group LLC now owns 2,237 shares of the medical equipment provider's stock worth $200,000 after acquiring an additional 129 shares during the period. Avantax Advisory Services Inc. boosted its holdings in shares of Lantheus by 5.9% in the fourth quarter. Avantax Advisory Services Inc. now owns 2,382 shares of the medical equipment provider's stock worth $213,000 after acquiring an additional 132 shares during the period. Foundry Partners LLC boosted its holdings in shares of Lantheus by 4.5% in the fourth quarter. Foundry Partners LLC now owns 3,103 shares of the medical equipment provider's stock worth $278,000 after acquiring an additional 133 shares during the period. Finally, UMB Bank n.a. raised its position in shares of Lantheus by 31.5% in the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock worth $50,000 after buying an additional 134 shares in the last quarter. 99.06% of the stock is owned by institutional investors.

Lantheus Price Performance

NASDAQ LNTH traded up $1.46 during trading hours on Friday, reaching $81.24. 913,883 shares of the stock traded hands, compared to its average volume of 981,515. The stock has a 50 day simple moving average of $97.11 and a two-hundred day simple moving average of $93.08. Lantheus Holdings, Inc. has a 1 year low of $75.00 and a 1 year high of $126.89. The company has a market cap of $5.62 billion, a price-to-earnings ratio of 13.52 and a beta of 0.23.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The firm had revenue of $372.76 million for the quarter, compared to analysts' expectations of $377.37 million. During the same quarter in the previous year, the business earned $1.69 EPS. The company's revenue for the quarter was up .8% on a year-over-year basis. On average, sell-side analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

LNTH has been the topic of a number of recent analyst reports. Truist Financial lowered their price objective on Lantheus from $127.00 to $117.00 and set a "buy" rating on the stock in a research report on Thursday, May 8th. StockNews.com upgraded Lantheus from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. Finally, B. Riley lowered their price objective on Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a research report on Friday, March 21st. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Lantheus currently has a consensus rating of "Buy" and a consensus target price of $132.67.

Insider Buying and Selling at Lantheus

In other news, CFO Robert J. Jr. Marshall sold 10,000 shares of the firm's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the transaction, the chief financial officer now directly owns 113,860 shares of the company's stock, valued at approximately $11,445,207.20. This trade represents a 8.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Mary Anne Heino sold 53,107 shares of the firm's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the transaction, the director now directly owns 440,399 shares in the company, valued at $41,551,645.65. This trade represents a 10.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 63,109 shares of company stock worth $6,016,046 over the last 90 days. Corporate insiders own 1.50% of the company's stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.